Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

ET-02, a PAI-1 inhibitor, is not proven to be more effective than Minoxidil for hair loss. Other treatments like finasteride, dutasteride, PP405, and AMP-303 are also discussed, focusing on cellular senescence and oxidative stress.

A study that outlines the full model for androgenic alopecia (AGA) which links DHT to cellular senescence in dermal papilla cells, and suggests black chokeberry as a source of cyanidin 3-O-arabinoside polyphenol with potential anti-oxidant properties that could reverse this process. The post encourages reaching out to experts in anti-aging and longevity to research treatments involving the polyphenol.

A user's 3-month experience with pyrilutamide to reduce hair shedding, and how it may not be strong enough to stop the thinning of their hairline. Other users mentioned the effectiveness of minoxidil and finasteride for treating hair loss.

PP405 may encourage earlier hair growth and slightly increase visible hair count but does not reverse hair follicle miniaturization in male pattern baldness. It does not address damage to the dermal papilla or broken Wnt signaling.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Concerns about the potential systemic effects and safety of PP405 for hair loss, with discussions on its comparison to existing treatments like finasteride and minoxidil. Users express skepticism about untested research chemicals and emphasize the importance of clinical trials to ensure safety and efficacy.

Finasteride and dutasteride are considered the best treatments for male pattern baldness, but they are not cures as they only slow hair loss. Other potential treatments like topical melatonin and natural DHT blockers are discussed, but aging and other factors like inflammation also play roles in hair loss.

Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.

Oleic acid and microneedling are being explored for hair regrowth, but results are mixed. Addressing DHT and fibrosis is crucial, with treatments like finasteride, minoxidil, and scalp massage also discussed.

DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.

Oral minoxidil may deplete collagen, potentially causing skin aging. Users discuss whether taking collagen supplements can counteract this effect.

The user started using finasteride, minoxidil, and biotin for male pattern baldness (MPB) and is experiencing rapid thinning. They are questioning if low blood flow to the head could be contributing to their hair loss.

Age affects hair loss severity and treatment effectiveness, with younger individuals often experiencing more aggressive loss but potentially better regrowth due to less follicle miniaturization. Treatments like finasteride and minoxidil are commonly used, and early intervention is crucial for better outcomes.

Finasteride is more effective for long-term hair maintenance by addressing the root cause of hair loss, while minoxidil acts as a growth stimulant with faster visible results. Combining both treatments is optimal, with oral minoxidil often showing better results for some individuals.

NMN shows promise in promoting hair growth by reducing oxidative stress and weakening androgens. It may be a beneficial addition to hair loss treatments like Minoxidil and Finasteride.

Alternating Dutasteride with pumpkin seed oil may protect the spleen from damage caused by Dutasteride. Pumpkin seed oil's antioxidants help counteract oxidative stress and immune suppression.

The conversation discusses the lack of public information on the chemical structure of PP405, a hair loss treatment, and the challenges of synthesizing it without a patent. It also explores a patent related to hydrogen-based topical formulations for reducing oxidative stress and inflammation.

Topical 2-deoxy-D-ribose (2dDR) regrows hair in mice almost as well as 2% Minoxidil. However, 2dDR may contribute to oxidative stress and hair loss due to the formation of advanced glycation end products (AGEs).

Astaxanthin (ASX) is highlighted as a promising supplement for treating hair loss due to its antioxidant properties. It may help with inflammation and oxidative stress, which are linked to hair loss and aging.

Korea launched its first OTC oral hair loss drug, dexpanthenol B5. Users discuss its anti-oxidative and anti-inflammatory effects but note a lack of efficacy studies.

Minoxidil's effectiveness may not be significantly impacted by high temperatures during shipping, as it undergoes stability tests to withstand extreme conditions. Users discuss concerns about oxidation and storage, but experts suggest that short-term exposure to heat is unlikely to degrade the product.

A user noticed a color change in their hair loss solution containing minoxidil, finasteride, retinoic acid, and hydrocortisone after storing it for several months. They are concerned about the effectiveness of the solution due to potential oxidation.

The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

Quitting smoking may improve the effectiveness of finasteride and minoxidil for hair regrowth. Smoking is harmful to hair health, potentially increasing hair loss and reducing regrowth.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

GHK-Cu is discussed as a potential hair loss treatment, with claims of promoting hair growth and possibly reversing gray hair, though strong clinical evidence is limited. The user also mentions using Minoxidil, red light therapy, and microneedling.

A new serum claims to enhance hair regrowth by amplifying oxygen delivery, improving the effectiveness of treatments like exosomes and peptides. Users are skeptical, questioning its efficacy compared to established treatments like Minoxidil and Finasteride.

PP405 is a potential new hair loss treatment that works through metabolic pathways rather than hormonal ones, with an estimated market release between late 2027 and 2029. Current alternatives to finasteride include minoxidil, pyralutamide, fluridil, and RU58841, with hair transplants also being a viable option.